
Global Life Science Ventures
Dr Bert van Toor has been appointed as investment manager for Global Life Science Ventures (GLSV). This appointment continues the planned expansion of the company's investment team in Europe to accommodate GLSV's increased geographic presence in Germany, Switzerland as well as the UK. As a member of the GLSV investment team, Dr van Toor will operate from the company's Zug office in Switzerland. He will be actively involved in evaluating potential investments, developing GLSV's portfolio of companies in the life sciences, and providing further counselling for the management of the fund. Van Toor has over 10 years of experience in senior level positions in the drug discovery and development industry. He qualified as a medical doctor at the University of Amsterdam in 1988 and obtained accreditation as a clinical pharmacologist in Mainz, Germany. He has worked for Boehringer Ingelheim and Bayer AG in several positions including global project management, clinical development and as interim medical director of the Benelux region.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Back to Top